Noteworthy Numbers

Web Exclusives - In the News

Increased awareness, earlier detection through screening, and advances in treatment have led to a decline in breast cancer death rates in the United States since 1990. Sadly, breast cancer continues to claim more women’s lives than any other cancer, besides lung cancer. For more statistical data on this prevalent disease, let’s take a look at breast cancer by the numbers.

About 1 in 8 (12%) women in the United States will develop invasive breast cancer over the course of her lifetime.

In 2010, an estimated 207,090 new cases of invasive breast cancer were expected to be diagnosed in women in the United States, along with 54,010 new cases of noninvasive breast cancer.

About 1970 new cases of invasive breast cancer were expected to be diagnosed in men in 2010…

Less than 1% of all new breast cancer cases occur in men. From 1999 to 2006, breast cancer incidence rates in the United States decreased by about 2% per year…

Besides skin cancer, breast cancer is the most commonly diagnosed cancer among US women…

More than 1 in 4 (about 28%) cancers in women are breast cancer.

Compared with African- American women, white women are slightly more likely to develop breast cancer, but less likely to die of it.

A woman’s risk of breast cancer approximately doubles if she has a first-degree relative who has been diagnosed with breast cancer…

About 20% to 30% of women diagnosed with breast cancer have this family history although some are attributed to chance.

About 5% to 10% of breast cancers can be linked to gene mutations inherited from one’s mother or father…

Mutations of the BRCA1 and BRCA2 genes are the most common…

Women with these mutations have up to an 80% risk of developing breast cancer during their lifetime, and they are more likely to be diagnosed at a younger age…

An increased ovarian cancer risk also is associated with these genetic mutations.

In men, about 1 in 10 breast cancers are believed to be associated with BRCA2 mutations and even fewer cases with BRCA1 mutations.

About 70% to 80% of breast cancers occur in women who have no family history of breast cancer.

The most significant risk factors for breast cancer are gender and age.

In 2010, there were more than 2.5 million breast cancer survivors in the United States.

Related Items
FDA News: July 2020
TOP - July 2020, Vol 13, No 4 published on July 15, 2020 in FDA Updates, In the News, Lung Cancer, Thyroid Cancer
CMS Expands Access to Telehealth Benefits During COVID-19 Outbreak
Web Exclusives published on March 18, 2020 in In the News, Healthcare Policy
FDA Grants Priority Review to New Drug Application for the RET Kinase Inhibitor Selpercatinib
Web Exclusives published on February 4, 2020 in FDA Updates, In the News, Lung Cancer, Thyroid Cancer
Tazverik Receives FDA Approval as First Treatment Specifically for Metastatic or Locally Advanced Epithelioid Sarcoma
Web Exclusives published on January 28, 2020 in FDA Updates, In the News, Sarcoma
Mixed Findings in Annual Cancer Statistics Report
Web Exclusives published on January 20, 2020 in In the News
FDA Grants Approval to Avapritinib for Patients with GIST
Web Exclusives published on January 13, 2020 in FDA Updates, Gastrointestinal Cancers, In the News, Rare Cancers
Recap of FDA Drug Approvals in 2019
Web Exclusives published on January 7, 2020 in FDA Updates, In the News
FDA Will Require Early Assessment of New Targeted Agents That May Be Used in Pediatric Cancers
Web Exclusives published on December 16, 2019 in In the News, Pediatric Cancer
Regenerative Medicine Advanced Therapy Designation Granted to ADP-A2M4 for Synovial Sarcoma
Web Exclusives published on December 11, 2019 in FDA Updates, In the News, Sarcoma
FDA Approves Adakveo to Reduce Vaso-Occlusive Crises in Patients with Sickle-Cell Disease
Web Exclusives published on November 25, 2019 in FDA Updates, In the News
Last modified: July 22, 2021